Trial · NCT00780715
Response To Oral Agents in Diabetes (ROAD)- Pilot Study
NCT00780715, Phase 4, Completed, University of Dundee; results first posted 2017-10-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Response To Oral Agents in Diabetes (ROAD)- Pilot Study. Trials, record NCT00780715. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00780715
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Response To Oral Agents in Diabetes (ROAD)- Pilot Study
- NCT number
- NCT00780715
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 29 participants, actual
- Lead sponsor
- University of Dundee
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Gliclazide MR, Sitagliptin, Pioglitazone, Metformin
- First posted
- 2008-10-28
- Last updated
- 2017-10-26
- Other registries' IDs
- eudract:2008-004790-18
- Results first posted
- 2017-10-26
- Limitations and caveats
Note that this study was a pilot study and was not designed or powered to show significance of differences in outcomes between groups. Primary aim was to demonstrate efficacy of novel route of recruitment from primary care.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | HbA1c Change | 6 months | Units are absolute difference in %HbA1c (HbA1c being the percentage of glycated Haemoglobin, reflecting glucose exposure over the last 3 months) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | HbA1c Change | 6 months | Modified Intention to treat | absolute change in %HbA1c | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| HbA1c Change | Gliclazide MR | -0.42 | Standard Deviation 0.72 | absolute change in %HbA1c | |
| HbA1c Change | Sitagliptin | -0.58 | Standard Deviation 0.63 | absolute change in %HbA1c | |
| HbA1c Change | Pioglitazone | -1.04 | Standard Deviation 0.71 | absolute change in %HbA1c | |
| HbA1c Change | Metformin | -1.59 | Standard Deviation 0.60 | absolute change in %HbA1c |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Gliclazide MR | 6 | |
| Overall Study | STARTED | Sitagliptin | 6 | |
| Overall Study | STARTED | Pioglitazone | 6 | |
| Overall Study | STARTED | Metformin | 11 | |
| Overall Study | COMPLETED | Gliclazide MR | 6 | |
| Overall Study | COMPLETED | Sitagliptin | 6 | |
| Overall Study | COMPLETED | Pioglitazone | 6 | |
| Overall Study | COMPLETED | Metformin | 11 | |
| Overall Study | NOT COMPLETED | Gliclazide MR | 0 | |
| Overall Study | NOT COMPLETED | Sitagliptin | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Gliclazide MR | 0 | 6 |
| Total, all-cause mortality | Sitagliptin | 0 | 6 |
| Total, all-cause mortality | Pioglitazone | 0 | 6 |
| Total, all-cause mortality | Metformin | 0 | 11 |
| Total, other adverse events | Gliclazide MR | 0 | 6 |
| Total, other adverse events | Sitagliptin | 0 | 6 |
| Total, other adverse events | Pioglitazone | 0 | 6 |
| Total, other adverse events | Metformin | 0 | 11 |
| Total, serious adverse events | Gliclazide MR | 0 | 6 |
| Total, serious adverse events | Sitagliptin | 0 | 6 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00780715
GET https://conductscience.org/api/trials/v1/NCT00780715/registered